Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding.

Authors

Shuo Feng, Shu-Xin Zhou, Zi-Lin Si, Yu-Min Cai, Yi-Fan Huangfu, Yi-Jia Hou, Zi-Tong Wang, Qi Liu, Hong-Xi Liu, Li-Juan Zhai, Tao He, Mao Gu, Gong-Hui Tan, Ao-Bo Zhang, Jun-Ling Zhao, Tao Xu, Yan Ling, Ying-Jian Hou, Xiao Zheng, Jing Li, Xing-Zhen Lao

Published in

Nature communications. Volume 17. Issue 1. May 04, 2026. Epub May 04, 2026.

Abstract

While the impact of non-antibiotic drugs on gut bacteria is well-known, their mechanisms of action remain poorly characterized, and effective mitigation strategies for drug-induced dysbiosis are still limited. Here, we screened bacteria-derived drug-target protein homologs (BDTPHs) mapped to 63 target proteins and 107 associated drugs to quantify "drug-BDTPH-bacterium" interactions. These interactions were validated by co-culture experiments using 10 drugs and 25 strains, enzyme assays, and genetic perturbations in Escherichia coli. Ex vivo and in vivo testing with six drugs showed that over 50% of affected genera exhibited high affinity, indicating microbiota alterations through the "drug-BDTPH-bacterium" axis. Leveraging this quantitative interaction framework, we identified a strain of Bifidobacterium animalis that can competitively bind methotrexate through high-affinity BDTPH, thereby effectively alleviating gut microbiota dysbiosis in vivo. Our findings elucidate a mechanism by which non-antibiotic drug effects on bacterial growth, and suggest a universal homology-based competition strategy to restore drug-disrupted microbiota.

PMID:
42082468
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.